Human strongyloidiasis in Hawaii

A retrospective review of enzyme-linked immunosorbent assay serodiagnostic testing

Matthew J. Akiyama, Joel D. Brown

Research output: Contribution to journalReview article

Abstract

Human strongyloidiasis is widely prevalent in tropical and subtropical regions worldwide but is not endemic in Hawaii. Subclinical, chronic infections may be lifelong; immunosuppressive therapy, particularly with glucocorticoids, may lead to serious or fatal disseminated disease, which is preventable. We performed a retrospective analysis of patients tested for Strongyloides immunoglobulin G antibody in an academic medical center in Honolulu, Hawaii, from 2005 to 2012. Of the 475 patients tested, 78 (16%) were seropositive. The largest proportion of seropositive cases was found among Micronesians (30%), Polynesians (26%), Filipinos (13%), and Southeast Asians (11%). Among the seropositive patients, the most likely reason for clinicians to order testing was blood eosinophilia. Stool parasite examination results were available for 58% of seropositive patients of which 11% were positive for Strongyloides stercoralis larvae. Anti-helminthic therapy, usually ivermectin, was ordered for 71% of patients. After treatment, blood eosinophilia and Strongyloides serology results were reassessed for 76% and 35% of patients, respectively; both tests tended to show improvement. Travelers and immigrants from Strongyloides-endemic areas, including Micronesia and Polynesia, should have serodiagnostic testing for latent strongyloidiasis, and if positive, treated empirically with ivermectin, particularly when corticosteroids or other immunosuppressive therapies are anticipated.

Original languageEnglish (US)
Pages (from-to)370-374
Number of pages5
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume99
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Strongyloidiasis
Enzyme-Linked Immunosorbent Assay
Strongyloides
Ivermectin
Eosinophilia
Immunosuppressive Agents
Therapy with Helminths
Pacific Islands
Strongyloides stercoralis
Asymptomatic Infections
Serology
Glucocorticoids
Larva
Adrenal Cortex Hormones
Parasites
Therapeutics
Immunoglobulin G
Antibodies

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Virology

Cite this

Human strongyloidiasis in Hawaii : A retrospective review of enzyme-linked immunosorbent assay serodiagnostic testing. / Akiyama, Matthew J.; Brown, Joel D.

In: American Journal of Tropical Medicine and Hygiene, Vol. 99, No. 2, 01.01.2018, p. 370-374.

Research output: Contribution to journalReview article

@article{e2a755718c3c4150be3ceddac8388fc4,
title = "Human strongyloidiasis in Hawaii: A retrospective review of enzyme-linked immunosorbent assay serodiagnostic testing",
abstract = "Human strongyloidiasis is widely prevalent in tropical and subtropical regions worldwide but is not endemic in Hawaii. Subclinical, chronic infections may be lifelong; immunosuppressive therapy, particularly with glucocorticoids, may lead to serious or fatal disseminated disease, which is preventable. We performed a retrospective analysis of patients tested for Strongyloides immunoglobulin G antibody in an academic medical center in Honolulu, Hawaii, from 2005 to 2012. Of the 475 patients tested, 78 (16{\%}) were seropositive. The largest proportion of seropositive cases was found among Micronesians (30{\%}), Polynesians (26{\%}), Filipinos (13{\%}), and Southeast Asians (11{\%}). Among the seropositive patients, the most likely reason for clinicians to order testing was blood eosinophilia. Stool parasite examination results were available for 58{\%} of seropositive patients of which 11{\%} were positive for Strongyloides stercoralis larvae. Anti-helminthic therapy, usually ivermectin, was ordered for 71{\%} of patients. After treatment, blood eosinophilia and Strongyloides serology results were reassessed for 76{\%} and 35{\%} of patients, respectively; both tests tended to show improvement. Travelers and immigrants from Strongyloides-endemic areas, including Micronesia and Polynesia, should have serodiagnostic testing for latent strongyloidiasis, and if positive, treated empirically with ivermectin, particularly when corticosteroids or other immunosuppressive therapies are anticipated.",
author = "Akiyama, {Matthew J.} and Brown, {Joel D.}",
year = "2018",
month = "1",
day = "1",
doi = "10.4269/ajtmh.18-0157",
language = "English (US)",
volume = "99",
pages = "370--374",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "2",

}

TY - JOUR

T1 - Human strongyloidiasis in Hawaii

T2 - A retrospective review of enzyme-linked immunosorbent assay serodiagnostic testing

AU - Akiyama, Matthew J.

AU - Brown, Joel D.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Human strongyloidiasis is widely prevalent in tropical and subtropical regions worldwide but is not endemic in Hawaii. Subclinical, chronic infections may be lifelong; immunosuppressive therapy, particularly with glucocorticoids, may lead to serious or fatal disseminated disease, which is preventable. We performed a retrospective analysis of patients tested for Strongyloides immunoglobulin G antibody in an academic medical center in Honolulu, Hawaii, from 2005 to 2012. Of the 475 patients tested, 78 (16%) were seropositive. The largest proportion of seropositive cases was found among Micronesians (30%), Polynesians (26%), Filipinos (13%), and Southeast Asians (11%). Among the seropositive patients, the most likely reason for clinicians to order testing was blood eosinophilia. Stool parasite examination results were available for 58% of seropositive patients of which 11% were positive for Strongyloides stercoralis larvae. Anti-helminthic therapy, usually ivermectin, was ordered for 71% of patients. After treatment, blood eosinophilia and Strongyloides serology results were reassessed for 76% and 35% of patients, respectively; both tests tended to show improvement. Travelers and immigrants from Strongyloides-endemic areas, including Micronesia and Polynesia, should have serodiagnostic testing for latent strongyloidiasis, and if positive, treated empirically with ivermectin, particularly when corticosteroids or other immunosuppressive therapies are anticipated.

AB - Human strongyloidiasis is widely prevalent in tropical and subtropical regions worldwide but is not endemic in Hawaii. Subclinical, chronic infections may be lifelong; immunosuppressive therapy, particularly with glucocorticoids, may lead to serious or fatal disseminated disease, which is preventable. We performed a retrospective analysis of patients tested for Strongyloides immunoglobulin G antibody in an academic medical center in Honolulu, Hawaii, from 2005 to 2012. Of the 475 patients tested, 78 (16%) were seropositive. The largest proportion of seropositive cases was found among Micronesians (30%), Polynesians (26%), Filipinos (13%), and Southeast Asians (11%). Among the seropositive patients, the most likely reason for clinicians to order testing was blood eosinophilia. Stool parasite examination results were available for 58% of seropositive patients of which 11% were positive for Strongyloides stercoralis larvae. Anti-helminthic therapy, usually ivermectin, was ordered for 71% of patients. After treatment, blood eosinophilia and Strongyloides serology results were reassessed for 76% and 35% of patients, respectively; both tests tended to show improvement. Travelers and immigrants from Strongyloides-endemic areas, including Micronesia and Polynesia, should have serodiagnostic testing for latent strongyloidiasis, and if positive, treated empirically with ivermectin, particularly when corticosteroids or other immunosuppressive therapies are anticipated.

UR - http://www.scopus.com/inward/record.url?scp=85051067331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051067331&partnerID=8YFLogxK

U2 - 10.4269/ajtmh.18-0157

DO - 10.4269/ajtmh.18-0157

M3 - Review article

VL - 99

SP - 370

EP - 374

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 2

ER -